Carlos E. Bueso‐Ramos

28.5k citations

386 papers · 14.7k indexed · 3 hit papers · h-index 59

Hematology top 0.05%
Molecular Biology top 1%
Genetics top 0.05%
Oncology top 0.5%
Pathology and Forensic Medicine top 0.2%

Co-authors: Hagop M. Kantarjian L. Jeffrey Medeiros Bharat B. Aggarwal Guillermo Garcia‐Manero Jörge E. Cortes George A. Călin Gabriel Lopez‐Berestein Jana Ferdin
Topics: Acute Myeloid Leukemia Research (198 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (88 papers)Lymphoma Diagnosis and Treatment (85 papers)
Cited by: Hematology Genetics Cancer Research
Journals: The Journal of Experimental Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States Germany China

In The Last Decade

Carlos E. Bueso‐Ramos

373 papers receiving 14.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNAs in body fluids—the mix of hormones and biomarkers

2011 1.2k citations Carlos E. Bueso‐Ramos, George A. Călin et al. profile →
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

2013 539 citations Carlos E. Bueso‐Ramos, Masoud Davanlou et al. profile →
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

2006 515 citations Hagop M. Kantarjian, Guillermo Garcia‐Manero et al. Blood profile →

Peers

Countries citing papers authored by Carlos E. Bueso‐Ramos

Since Specialization

Citations

This map shows the geographic impact of Carlos E. Bueso‐Ramos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos E. Bueso‐Ramos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos E. Bueso‐Ramos more than expected).

Fields of papers citing papers by Carlos E. Bueso‐Ramos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos E. Bueso‐Ramos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos E. Bueso‐Ramos. The network helps show where Carlos E. Bueso‐Ramos may publish in the future.

Co-authorship network of co-authors of Carlos E. Bueso‐Ramos

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos E. Bueso‐Ramos. A scholar is included among the top collaborators of Carlos E. Bueso‐Ramos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos E. Bueso‐Ramos. Carlos E. Bueso‐Ramos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multimodal spatial proteomic profiling in acute myeloid leukemia 2025 ·npj Precision Oncology ·(unknown),(unknown),(unknown),(unknown),Fatima Zahra Jelloul,Sammy Ferri‐Borgogno,(unknown),Javier A. Gomez,(unknown),Patrick K. Reville,Sonali Jindal,Sreyashi Basu,Padmanee Sharma,Andres Quesada,Carlos E. Bueso‐Ramos,Taghi Manshouri,Branko Cuglievan,(unknown),Jared K. Burks,Hussein A. Abbas	0
2	Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma 2024 ·Blood ·Qing Wei,Carlos E. Bueso‐Ramos	0
3	Myeloid/lymphoid neoplasms with FLT3 rearrangement 2021 ·Modern Pathology ·Guilin Tang,Wayne Tam,Nicholas J. Short,Prithviraj Bose,David Wu,Stephanie N. Hurwitz,Adam Bagg,Heesun J. Rogers,Eric D. Hsi,Andres Quesada,Wei Wang,Roberto N. Miranda,Carlos E. Bueso‐Ramos,L. Jeffrey Medeiros,Valentina Nardi,Robert P. Hasserjian,Daniel A. Arber,Attilio Orazi,Kathryn Foucar,Sa A. Wang	25
4	Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study 2020 ·American Journal of Hematology ·Heesun J. Rogers,Xiaoqiong Wang,Yan Xie,Adam R. Davis,Beenu Thakral,Sa A. Wang,Gautam Borthakur,(unknown),Elizabeth Margolskee,(unknown),Madina Sukhanova,Adam Bagg,Carlos E. Bueso‐Ramos,Attilio Orazi,Daniel A. Arber,Eric D. Hsi,Robert P. Hasserjian	22
5	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma 2020 ·Human Pathology ·Kirill A. Lyapichev,Guilin Tang,Shaoying Li,M. James You,(unknown),Roberto N. Miranda,Swaminathan P. Iyer,C. Cameron Yin,Sergej Konoplev,Carlos E. Bueso‐Ramos,Francisco Vega,L. Jeffrey Medeiros,Jie Xu	10
6	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 2020 ·Modern Pathology ·Andres Quesada,Guillermo Montalban‐Bravo,Rajyalakshmi Luthra,Keyur P. Patel,Koji Sasaki,Carlos E. Bueso‐Ramos,Joseph D. Khoury,Mark J. Routbort,Roland L. Bassett,(unknown),Chong Zhao,Pei Lin,Sanam Loghavi,Chi Young Ok,Tapan M. Kadia,Courtney D. DiNardo,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Rashmi Kanagal‐Shamanna	13
7	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease 2019 ·American Journal of Hematology ·Andres Quesada,Mark J. Routbort,Courtney D. DiNardo,Carlos E. Bueso‐Ramos,Rashmi Kanagal‐Shamanna,Joseph D. Khoury,Beenu Thakral,Zhuang Zuo,C. Cameron Yin,Sanam Loghavi,Chi Young Ok,Sa A. Wang,Zhenya Tang,Sarah A. Bannon,Christopher B. Benton,Guillermo Garcia‐Manero,Hagop M. Kantarjian,Rajyalakshmi Luthra,L. Jeffrey Medeiros,Keyur P. Patel	71
8	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation 2018 ·Cancer ·Rashmi Kanagal‐Shamanna,Preetesh Jain,Keyur P. Patel,Mark J. Routbort,Carlos E. Bueso‐Ramos,(unknown),Joseph D. Khoury,Rajyalakshmi Luthra,Alessandra Ferrajoli,Michael J. Keating,Nitin Jain,Jan A. Burger,Zeev Estrov,William G. Wierda,Hagop M. Kantarjian,L. Jeffrey Medeiros	77
9	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation 2018 ·Leukemia Research ·Yasmin Abaza,(unknown),Srđan Verstovšek,(unknown),Farhad Ravandi,Gautam Borthakur,Zeev Estrov,Yesid Alvarado,Jan A. Burger,Heather Schneider,Kelly A. Soltysiak,Yue Wei,Hagop M. Kantarjian,Carlos E. Bueso‐Ramos,Guillermo Garcia‐Manero	8
10	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 2018 ·Cancer ·Hagop M. Kantarjian,Courtney D. DiNardo,Graciela M. Nogueras‐González,Tapan M. Kadia,Elias Jabbour,Carlos E. Bueso‐Ramos,Susan O’Brien,Marina Konopleva,Nitin Jain,Naval Daver,Elizabeth J. Shpall,Richard E. Champlin,(unknown),Guillermo Garcia‐Manero,Michael J. Keating,Xuelin Huang,Jörge E. Cortes,Sherry Pierce,Farhad Ravandi,Emil J. Freireich	20
11	T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas 2017 ·American Journal of Clinical Pathology ·Tanu Goyal,Beenu Thakral,Sa A. Wang,Carlos E. Bueso‐Ramos,Min Shi,Dragan Jevremović,William G. Morice,(unknown),Tracy I. George,(unknown),Siddharth Bhattacharyya,Adam Bagg,Heesun J. Rogers,Juraj Bodo,Lisa Durkin,Eric D. Hsi	13
12	Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy 2016 ·Blood ·Wei Wang,Jörge E. Cortes,Guilin Tang,Joseph D. Khoury,Sa Wang,Carlos E. Bueso‐Ramos,Joseph A. DiGiuseppe,Zi Chen,Hagop M. Kantarjian,L. Jeffrey Medeiros,Shimin Hu	111
13	Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens 2015 ·Clinical Cancer Research ·(unknown),Diana E. Jaalouk,Carlos E. Bueso‐Ramos,Laura Bover,Yan Sun,Akihiko Kuniyasu,Wouter H. P. Driessen,Marina Cardó‐Vila,Cecilia Rietz,Amado J. Zurita,Susan O’Brien,Hagop M. Kantarjian,Jörge E. Cortes,George A. Călin,Erkki Koivunen,Wadih Arap,Renata Pasqualini	11
14	Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients 2015 ·Human Pathology ·Mariko Yabe,L. Jeffrey Medeiros,Guilin Tang,Sa A. Wang,Keyur P. Patel,Mark J. Routbort,Govind Bhagat,Carlos E. Bueso‐Ramos,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Weina Chen,Tariq Muzzafar,Rashmi Kanagal‐Shamanna,Joseph D. Khoury,Yahya Daneshbod,Masoud Davanlou,Shaoying Li,Ken H. Young,Roberto N. Miranda	11
15	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response 2014 ·European Journal Of Haematology ·Qi Shen,Juan Ouyang,Guilin Tang,Elias Jabbour,Guillermo Garcia‐Manero,Mark J. Routbort,Sergej Konoplev,Carlos E. Bueso‐Ramos,L. Jeffrey Medeiros,Jeffrey L. Jorgensen,Sa A. Wang	24
16	Epstein‐Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia 2010 ·Cancer ·Jeffrey J. Tarrand,Michael J. Keating,Apostolia M. Tsimberidou,Susan O’Brien,(unknown),(unknown),Carlos E. Bueso‐Ramos	21
17	Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma and Acute Biphenotypic Leukemias 2007 ·American Journal of Clinical Pathology ·(unknown),Carlos E. Bueso‐Ramos	1
18	Precursor T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma and Acute Biphenotypic Leukemias 2007 ·American Journal of Clinical Pathology ·Xin Han,Carlos E. Bueso‐Ramos	27
19	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome 2007 ·Cancer ·Hagop M. Kantarjian,Susan O’Brien,Xuelin Huang,Guillermo Garcia‐Manero,Farhad Ravandi,Jörge E. Cortes,Jianqin Shan,Jan Davisson,Carlos E. Bueso‐Ramos,Jean‐Pierre J. Issa	132
20	CD56 TdT blastic natural killer cell tumor of the skin 2002 ·Cancer ·Joseph D. Khoury,L. Jeffrey Medeiros,John T. Manning,(unknown),Carlos E. Bueso‐Ramos,Dan Jones	1

About Carlos E. Bueso‐Ramos

Carlos E. Bueso‐Ramos is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 386 papers that have together received 14.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (198 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (88 papers) and Lymphoma Diagnosis and Treatment (85 papers). The work is most often cited by research in Hematology (6.0k citations), Genetics (4.3k citations) and Cancer Research (2.4k citations). Carlos E. Bueso‐Ramos has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Hagop M. Kantarjian, L. Jeffrey Medeiros, Bharat B. Aggarwal, Guillermo Garcia‐Manero, Jörge E. Cortes, George A. Călin, Gabriel Lopez‐Berestein, Jana Ferdin, María Angélica Cortez and Anil K. Sood. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact